Klinik für Urologie und Kinderurologie

Studien zur überaktiven Blase und Harnblasenkarzinom

A NIS of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer

Studien-Status: geöffnet

Weitere Informationen finden Sie hier. 

A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Studien-Status: geöffnet

Weitere Informationen finden Sie hier. 

A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

An Open-label, Multi-center, Phase I/II Study of MFA-370 in Patients With Metastatic Urothelial Cancer

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)

Studien-Status: ist geöffnet

Weitere Informationen finden Sie hier.

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

 
 
 
 

Kontakt

Barbara Thielen (Ltd. study nurse)
Ansgar Nehus (study nurse)
Michael Grenzebach (study nurse)
Anika Kunz (study nurse)

Terminvereinbarung
Montag bis Freitag: 10 - 15 Uhr
E uroonkologie@ukmuenster.de
T +49 (0)251- 83 48 12 6

IN NOTFÄLLEN
T +49 (0)251- 83 47 44 6 oder
T +49 (0)251- 83 48 00 1